The trajectory of Sildenafil presents a challenging picture for shareholders. While the initial launch generated significant profits, the lapse of its intellectual property protection opened the floodgates to cheaper https://esmeerbdh285202.blogdeazar.com/42174864/sildenafil-and-pharma-a-risky-investment